Tenon Medical Inc. Common Stock Earnings Recaps
Q1 2026
May 16, 2026
Tenon Medical’s stock dropped 11% as investors reacted negatively to cautious outlook signals overshadowing the revenue growth and margin expansion. Despite record first-quarter revenue and gross margin gains, elevated operating expenses and lack of clear forward guidance likely disappointed the market.
Key takeaways
- Q1 revenue nearly doubled year-over-year to $1.4 million, driven by increased Catamaran procedure volumes and the first full quarter of SImmetry+ contribution.
- Gross margin expanded significantly to 68.5%, up 24 percentage points from a year ago, benefiting from higher revenue absorption of fixed overhead and streamlined commercial operations.
- Operating expenses rose slightly to $4.2 million, largely due to increased sales and marketing spend supporting the SImmetry+ rollout and higher R&D investment tied to product development.
- Net loss narrowed modestly to $3.5 million ($0.31 per share), with per-share improvement influenced by a larger share count but reflecting a real dollar loss reduction.
- No definitive upward guidance was provided for the near term; cost structure improvements may be offset by ongoing investment needs and potential growth execution risks.
Q3 2025
Nov 14, 2025
Tenon Medical demonstrated robust growth in Q3 2025, achieving record revenues of $1.2 million, a 32% increase year-over-year, driven by high demand for its innovative sacroiliac joint fusion solutions.
Key takeaways
- Successful integration of CyVantage's Symmetry portfolio contributed to top-line growth, marking a pivotal point in Tenon’s strategic expansion.
- Full commercial launch of the Catamaran SE system showcased enhanced functionality, addressing varied patient needs and improving competitive positioning.
- Positive clinical outcomes from the ongoing main sales study further validated the efficacy of the Catamaran system, with statistically significant improvements in patient pain and disability scores.
- Tenon received FDA 510(k) clearance for the Symmetry Plus system, enhancing its product offerings and preparing for the upcoming alpha launch.
- Cash position remained strong at $3.4 million with no debt, supplemented by a recent $2.85 million investment.